Despite these achievements, Needham reiterated its Hold rating for Moderna on October 20, 2025, with the stock price at $26.01, as reported by StreetInsider. The stock reached a high of$26.91 on the same day, reflecting market interest and the company's ongoing developments. Moderna has been recognized as a top employer in the biopharmaceutical industry for the eleventh consecutive year. The company achieved a significant milestone with the approval of mNEXSPIKE, a new COVID-19 vaccine. Despite these achie ...